In ovarian cancer specifically, preclinical studies and early trials with IL1 inhibitors like Anakinra suggest potential benefits in reducing the IL1–IL6 inflammatory loop, which promotes tumor growth and immune evasion. This evidence concerns the gene IL1A and ovarian carcinoma.